Systemic lupus erythematosus trials: Successes and issues

Current Opinion in Rheumatology

Volumn 16, Issue 5, 2004, Pages 499-504

  Ginzler, Ellen M ^a   Moldovan, Ioana ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Biologics; Clinical trials; Immunosuppressive drugs; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

ABETIMUS; AZATHIOPRINE; BELIMUMAB; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRASTERONE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG;

ACNE; AMENORRHEA; ARTERY THROMBOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GONAD DYSFUNCTION; HERPES ZOSTER; HORMONE SUBSTITUTION; HUMAN; INFECTION; KIDNEY DISEASE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHATIC SYSTEM TUMOR; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NAUSEA; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; STATISTICAL SIGNIFICANCE; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID CARCINOMA; TOXICITY; UTERINE CERVIX CARCINOMA; VEIN THROMBOSIS; VOMITING;

BIOLOGICAL PRODUCTS; CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RHEUMATOLOGY;

EID: 4344613555     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000133659.14482.59     Document Type: Review

References (43)

1. Petri M, Lahita RG, van Vollenhoven RF, et al.: Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus. Arthritis Rheum 2002, 46:1820-1829.
2. Chang DM, Lan JL, Lin HY, et al.: Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus. Arthritis Rheum 2002, 46:2924-2927.
3. Tseng C, Buyon J, Belmont HM, et al.: Moderate dose steroids prevent severe flares of serologically active, clinically stable SLE patients. Arthritis Rheum 2003, 48:S260. In stable patients with SLE, changes in C3a and anti-dsDNA levels are predictive of clinical flares, which can be suppressed with moderate-dose steroids.
4. Houssiau FA, Vasconcelos C, D'Cruz D, et al.: Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46:2121-2131.
5. Illei GG, Takada K, Parkin D, et al.: Renal flares are common in patients with severe proliferative lupus nephritis treated with immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002, 46:995-1002.
6. Al Salloum AA: Cyclophosphamide therapy for lupus nephritis: poor renal survival in Arab children. Pediatr Nephrol 2003, 18:357-361.
7. Lehman TJ, Edelheit BS, Onel KB: Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis 2004, 63:321-323.
8. Barbano G, Gusmano R, Damasio B, et al.: Childhood-onset lupus nephritis: a single-center experience of pulse intravenous cyclophosphamide therapy. J Nephrol 2002, 15:123-129.
9. Dooley MA, Hogan S, Jennette C, et al.: Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997, 51:1188-1195.
10. Williams W, Bhagwandass A, Sargeant LA, et al.: Severity of systemic lupus erythematosus with diffuse proliferative glomerulonephritis and the ineffectiveness of standard pulse intravenous cyclophosphamide therapy in Jamaican patients. Lupus 2003, 12:640-645.
11. Velasquez X, Verdejo U, Massardo L, et al.: Outcome of Chilean patients with lupus nephritis and response to intravenous cyclophosphamide. J Clin Rheumatol 2003, 9:7-14.
12. Barr RG, Seliger S, Appel GB, et al.: Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 2003, 18:2039-2046. This retrospective review of a large series of patients with proliferative lupus nephritis points out the important association of poverty with poor outcome.
13. Alba P, Karim MY, Hunt BJ: Mycophenolate mofetil as a treatment for autoimmune hemolytic anemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003, 12:633-635.
14. Samad AS, Lindsley CB: Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil. South Med J 2003, 96:705-707.
15. Kapitsinou PP, Boletis JN, Skopouli FN, et al.: Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology 2004, 43:377-380. In this retrospective review of 18 patients with LN, MMF appeared to be safe and effective in those with proliferative histology, whereas efficacy in membranous LN was not observed.
16. Riskalla M, Somers EC, Fatica RA, et al.: Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003, 30:1508-1512. This retrospective review of 54 consecutive patients treated with MMF describes the most common side effects of this agent and the reasons for drug discontinuation.
17. Doria A, Frassi M, Della Libera S, et al.: Prospective study on tolerability and efficacy of mycophenolate mofetil (MMF) in SLE. Arthritis Rheum 2003, 48:S587. This prospective review of 42 patients, some with refractory manifestations of active lupus and others with newly diagnosed nephritis, found MMF therapy to be well tolerated and effective in reducing overall disease activity.
18. Ferro ML, Karim MY, Abbs IC, et al.: Mycophenolate mofetil: a potential treatment for reducing proteinuria associated with membranous lupus nephritis. Arthritis Rheum 2003, 48:S588.
19. Chan TM, Li FK, Tang CSO, et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000, 343:1156-1162.
20. Hu W, Liu Z, Chen H, et al.: Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J 2002, 115:705-709.
21. Ginzler EM, Aranow C, Merrill JT, et al.: Toxicity and tolerability of mycophenolate mofetil (MMF) versus intravenous cyclophosphamide (IVC) in a multi-center trial as induction therapy for lupus nephritis (LN). Arthritis Rheum 2003, 48:S586. In a randomized, open-label trial of 140 patients with severe LN, MMF was found to be superior to IV CYC in inducing complete remissions, with better patient tolerability.
22. Contreras G, Pardo V, Leclercq B, et al.: Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004, 350:971-980. In patients with proliferative LN, induction therapy with IV CYC followed by maintenance therapy with either MMF or AZA appeared to be more efficacious and safer than long-term IV CYC.
23. Saito K, Nawata M, Nakayamada S, et al.: Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 2003, 12:798-800.
24. Saigal K, Valencia IC, Cohen J, et al.: Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab. J Am Acad Dermatol 2003, 49:S283-S285.
25. Perrotta S, Locatelli F, La Manna A, et al.: Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune hemolytic anemia in a patient with systemic lupus erythematosus. Br J Haematol 2002, 116:465-467.
26. Weide R, Heymans J, Pandorf A, et al.: Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003, 12:779-782.
27. Eisenberg R: Rituximab in lupus. Arthritis Res Ther 2003, 5:157-159. This review outlines the pathophysiologic basis for which rituximab has been used in the treatment of SLE.
28. Leandro MJ, Edwards JE, Cambridge G, et al.: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2673-2677.
29. Leandro MJ, Ehrenstein MR, Edwards JCW, et al.: Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis Rheum 2003, 48:S378.
30. Anolik JH, Campbell D, Felgar R, et al.: B lymphocyte depletion in the treatment of systemic lupus (SLE); phase I/II trial of rituximab (Rituxan in SLE). Arthritis Rheum 2002, 46:S717.
31. Alarcon-Segovia D, Tumlin AJ, Furie R, et al.: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:442-454. LJP 394, a B-cell tolerogen against anti-dsDNA antibodies, was compared with placebo in a large trial of patients with prior LN. A difference in flare rates did not reach statistical significance.
32. Strand V, Aranow C, Cardiel MH, et al.: Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003, 12:677-686.
33. Furie R, Stohl W, Ginzler E, et al.: Safety, pharmacokinetics and pharmacodynamic results of a phase I single and double dose-escalation study of LymphoStat B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 2003, 48:S377.
34. Hirashima M, Fukasawa T, Abe K, et al.: Expression and activity analyses of CTLA4 in peripheral blood lymphocytes in systemic lupus erythematosus patients. Lupus 2004, 13:24-31.
35. Foell J, Strahontin S, O'Neil SP, et al.: CD137 costimulatory T cell receptor engagement reverses acute disease in lupus prone NZB x NZW F1 mice. J Clin Invest 2003, 111:1505-1518.
36. Genovese MC, Uhrin Z, Bloch DA, et al.: Long-term follow-up of patients treated with total lymphoid irradiation for lupus nephritis. Arthritis Rheum 2002, 46:1014-1018.
37. Traynor AE, Barr WG, Rosa RM, et al.: Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 2002, 46:2917-2923.
38. Lisukov IA, Sizikova SA, Kulagin AD, et al.: High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus. Lupus 2004, 13:89-94. This series of six SLE patients treated with stem cell transplantation suggests that long-term, steroid-free remissions are possible, but early mortality is not uncommon.
39. Petri M, Jones RJ, Brodsky RA: High-dose cyclophosphamide without stem cell transplant in systemic lupus erythematosus. Arthritis Rheum 2003, 48:166-173. In an uncontrolled series of 14 patients with refractory features of SLE, high-dose CYC without stem cell transplantation resulted in rapid hematopoietic reconstitution with significant clinical benefit.
40. Karassa FB, Tatsioni A, Ioannidis JPA: Design, quality, and bias in randomized controlled trials of systemic lupus erythematosus. J Rheumatol 2003, 30:979-984. This excellent review of all published, randomized, clinical trials in SLE identifies the problematic issues in the design and reporting of studies, which need to be considered in improving the quality of subsequent trials.
41. Bronson K, Petri M, Brodsky R, et al.: High-dose cyclophosphamide is preferable to monthly IV cyclophosphamide at six months. Arthritis Rheum 2003, 48:S588.
42. Edworthy SM, Dobkin PL, Clarke AE, et al.: Group psychotherapy reduces illness intrusiveness in systemic lupus erythematosus. J Rheumatol 2003, 30:1011-1016.
43. Tench CM, McCarthy J, McCurdie, et al.: Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology 2003, 42:1050-1054.